What should you know about non methylated glioblastoma?

Glioblastoma is an aggressive brain tumour. The MGMT promoter test looks at a chemical pattern in tumour cells. When it is not methylated, the tumour may be less likely to respond to temozolomide, a chemotherapy medicine, than a methylated tumour. This result is one part of the picture; it does not by itself determine an individual's treatment or future.

The team also considers where the tumour sits, whether it can be safely removed, scan findings, neurological symptoms, age, general health and the person's wishes. Testing is performed on tumour tissue and is interpreted with the pathology report.

Ask the neuro-oncology team to explain the MGMT wording alongside the full pathology and scan results. Care may include brain tumour surgery when removal or biopsy can be done safely, followed by radiotherapy and drug treatment. Rehabilitation can support speech, movement, memory or daily activities when these are affected.

Keep a written list of medicines and symptoms, and ask who to contact if seizures, headaches, weakness or confusion change. A specialist can also explain whether a clinical trial is suitable for the tumour's features and your goals.

Seek emergency help for a first seizure, a seizure lasting longer than usual, sudden weakness on one side, new trouble speaking, severe confusion, repeated vomiting, or a rapidly worsening headache. Contact the treating team promptly for a new or changing symptom, even when it seems mild.

Which findings besides MGMT status are guiding my plan? Is surgery intended for diagnosis, tumour removal, or both? What benefits and side effects should I expect from radiotherapy or chemotherapy? Would a clinical trial fit my situation? What symptoms should prompt a same-day call?